Search, Find and Buy Antibodies, ELISA Kits and Proteins.
Loading Loading
Order hotline:
phone +1 404 474 4654
fax +1 888 205 9894 (TF)
Details for Product No. ABIN350932

Synuclein, alpha Interacting Protein (SNCAIP) (Internal Region) antibody

Request
Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms SYPH1, Sph1, Syph1, 2810407O15Rik, 4933427B05Rik, BB104594, sncaip, MGC88953, SNCAIP, LOC100221074
Epitope
»Alternatives Internal Region
Reactivity
»Alternatives Human
Host
»Alternatives Rabbit
Clonality Polyclonal
Conjugate
»Alternatives Un-conjugated
Application
»Alternatives Immunohistochemistry (IHC), Western Blotting (WB)
Pubmed 5 references available
Catalog no. ABIN350932
Quantity 500 µg
Price
454.67 $   Plus shipping costs $45.00
Shipping to
Availability Will be delivered in 7 to 8 Business Days
Immunogen A synthetic peptide from the internal region of human Synphilin-1 (Synphilin 1, alpha synuclein interacting protein) conjugated to an immunogenic carrier protein was used as the immunogen.
Isotype IgG
Specificity Appears to be specific for Synphilin-1.
Purity IgG
Alternative Name Synphilin-1 (Synphilin 1,alpha synuclein interacting protein)
Background Tissue specificity: Widely expressed, with highest levels in brain, heart and placenta. Defects in SNCAIP are a cause of Parkinson disease (PD). PD is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. Constructs encoding portions of SNCA and SNCAIP co-transfected in mammalian cells promote cytosolic inclusions resembling the Lewy bodies of Parkinson disease. Coexpression of SNCA, SNCAIP, and PARK2 result in the formation of Lewy body-like ubiquitin-positive cytosolic inclusions. Familial mutations in PARK2 disrupt the ubiquitination of SNCAIP and the formation of the ubiquitin-positive inclusions. These results provide a molecular basis for the ubiquitination of Lewy body-associated proteins and link PARK2 and SNCA in a common pathogenic mechanism through their interaction with SNCAIP. Also known as: Alpha-synuclein-interacting protein, SNCAIP.
UniProt Q9Y6H5
Application Notes IHC, WB. A concentration of 10-50 µg/ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.
Restrictions For Research Use only
Format Lyophilized
Storage -20 °C
Engelender, Wanner, Kleiderlein et al.: "Organization of the human synphilin-1 gene, a candidate for Parkinson's disease." in: Mammalian genome : official journal of the International Mammalian Genome Society, Vol. 11, Issue 9, pp. 763-6, 2000 (PubMed).

Chung, Zhang, Lim et al.: "Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease." in: Nature medicine, Vol. 7, Issue 10, pp. 1144-50, 2001 (PubMed).

Ito, Niwa, Hishikawa et al.: "Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1." in: The Journal of biological chemistry, Vol. 278, Issue 31, pp. 29106-14, 2003 (PubMed).

Nagano, Yamashita, Takahashi et al.: "Siah-1 facilitates ubiquitination and degradation of synphilin-1." in: The Journal of biological chemistry, Vol. 278, Issue 51, pp. 51504-14, 2003 (PubMed).

Imami, Sugiyama, Kyono et al.: "Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column." in: Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, Vol. 24, Issue 1, pp. 161-6, 2008 (PubMed).

Alternatives for antigen "Synuclein, alpha Interacting Protein (SNCAIP)", type "Antibodies"
Hosts (38), (11), (3)
Reactivities (48), (22), (13), (12), (12), (12), (12), (12)
Applications (36), (19), (13), (12), (10), (4), (2), (2), (1)
Conjugates (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Epitopes (14), (4), (2), (2), (2), (2), (1), (1)
Beacon